Key takeaways • Real-world evidence (RWE) has the potential to be useful across the entire healthcare ecosystem, including for clinical trials, care provision, determining treatment outcomes, and post-care safety monitoring. However, impact potential is relative to the quality and quantity of data available for analysis.
We have tracked 57 startups that we view as primarily focused on RWE business opportunities. Since 2019, these startups have raised $1.8 billion in VC and have an aggregate valuation of $16.0 billion (although valuations are not available for many of these companies).
We forecast the RWE solutions market to grow at a 15% CAGR from $1.1 billion in 2020 to $2.9 billion in 2027.
Key startups opportunities include building proprietary datasets, developing real-world data (RWD) analytical tools, and creating data standardization and management solutions.
top of page
bottom of page